A researcher at Yale has identified a novel biomarker in serum that, along with another commonly assessed physiological indicator can differentiate patients with schizophrenia from healthy individuals and those with major depression. The biomarker results are interpreted by an index, which is based upon a clear physiological dysfunction. The biomarker levels in subjects with schizophrenia show a distinctly different response pattern than both healthy controls and subjects with depression. The results indicate the sensitivity and specificity of this biomarker to remarkably distinguish between the groups tested, in particular for identifying individuals with schizophrenia. Patients who are considered to be “prodromal” or who are undergoing initial intervetion can be screened or monitored, respectively, using this test and scoring matrix.
The present invention includes a method for diagnosing cancer and predicting recurrent cancer comprising detecting the presence of survivin in the biological fluid of a patient.
The present invention provides methods for identifying patients at risk of developing preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.
The present invention provides methods and compositions related to biomarker profiles for each trimester of pregnancy. The present invention also provides methods for identifying patients at risk of developing a complication of pregnancy, such as preeclampsia. In further embodiments, the present invention relates to methods for the diagnosis of patients with preeclampsia.